Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion
Information source: Hadassah Medical Organization
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Central Retinal Vein Occlusion
Intervention: Retinal endo vascular surgery (Procedure)
Status: Not yet recruiting
Sponsored by: Hadassah Medical Organization
Official(s) and/or principal investigator(s):
Michael halpert, Study Chair, Affiliation: Hadassah Medical Organization
Michael Halpert, MD., Phone: 00972507874385, Email: firstname.lastname@example.org
Patients with Central Retinal Vein Occlusion will undergo vitrectomy, a small needle of about
71 micron will enter a branch retinal vein and TPA will be injected into the obstracted
Study design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment
Amount of macular edema.
Patients with Central Retinal Vein Occlusion less than 6 month duration and reduction of
vision to 6/21 will go OCT and FANG examinations.
Patient will be operated vitrectomy, and a branch retinal vein will be punctured by small
needle and rTPA 200mcg/ml will be injected to the vein.
Minimum age: 18 Years.
Maximum age: N/A.
- crvo less than 6 month
- Visual Acuity less than 6/21
- No prior eye surgery except cataract.
- Retinal/iris neovascularization
Locations and Contacts
Michael Halpert, MD., Phone: 00972507874385, Email: email@example.comAdditional Information
Starting date: October 2006
Ending date: October 2007
Last updated: October 3, 2006